We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
638 - Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial.
- Authors
Simpson, Eric L; Eichenfield, Lawrence F; Papp, Kim A; Forman, Seth; Hebert, Adelaide A; Gonzalez, Mercedes E; Gooderham, Melinda; Hong, H Chih-ho; Prajapati, Vimal H; Guttman, Emma; Silverberg, Jonathan; Seal, Melissa; Krupa, David; Burnett, Patrick; Synder, Scott; Chu, David H; Higham, Robert C; Berk, David R
- Abstract
Background Roflumilast, a highly potent phosphodiesterase-4 inhibitor, is being investigated as a non-steroidal, once-daily cream for atopic dermatitis (AD). Methods INTEGUMENT-OLE (NCT04804605) was an open-label 52-week safety trial. Patients (N=658) with mild to moderate AD who completed a 4-week randomized vehicle-controlled phase 3 trial of roflumilast cream continued or switched to once-daily roflumilast cream 0.15% in this open-label extension trial. Starting at Week 4, patients achieving Validated Investigator Global Assessment for AD (vIGA-AD) score of 0 (Clear) switched to twice-weekly (BIW) maintenance dosing. The primary endpoint was safety; secondary endpoints included vIGA-AD, Worst Itch-Numeric Rating Scale (WI-NRS), and Eczema Area and Severity Index (EASI). "Disease control" was defined as duration of vIGA-AD=0/1 on BIW dosing following achievement of vIGA-AD=0. Results With cumulative treatment up to 56 weeks, 36.7% of patients reported treatment-emergent adverse events (AEs); most were mild to moderate in severity. Overall, 4.7% of patients had AEs deemed treatment-related and 3.0% discontinued due to AEs. The most common AEs (>2%) were COVID-19, upper respiratory tract infection, nasopharyngitis, and headache. At Week 52, 55.7%, 61.1%, and 53.6% of patients achieved vIGA-AD=0/1 (Clear/Almost Clear), ≥75% reduction in EASI, and ≥4-point reduction in WI-NRS (among patients aged ≥12 years with baseline WI-NRS ≥4), respectively. Of the 130 (19.8%) patients who achieved disease control, 50% maintained "disease control" for at least 281 days. Conclusion Treatment with roflumilast cream 0.15% demonstrated long-term safety in patients with AD consistent with parent trials and durable efficacy through 52 weeks, including patients who switched to BIW dosing.
- Subjects
RESPIRATORY infections; CLINICAL trials; PHOSPHODIESTERASE inhibitors; ATOPIC dermatitis; PATIENT safety
- Publication
British Journal of Dermatology, 2024, Vol 191, p1
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1093/bjd/ljae266.019